Acadia Pharmaceuticals vs BioMarin Pharmaceutical
ACAD and BMRN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACAD and BMRN compare
BioMarin Pharmaceutical is the larger company, worth 3.4 times as much as Acadia Pharmaceuticals ($11.1B against $3.2B).
On earnings, Acadia Pharmaceuticals is cheaper: it trades at 8.9× trailing earnings, against 151× for BioMarin Pharmaceutical.
Acadia Pharmaceuticals grew revenue faster over the last twelve months (14.8% versus 11.2% for BioMarin Pharmaceutical).
Acadia Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 30.1% compared with 2.1% at BioMarin Pharmaceutical.
Acadia Pharmaceuticals scores higher on the StockData Score (17 against 8 for BioMarin Pharmaceutical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACAD | BMRN |
|---|---|---|
| Size and price | ||
| Market cap | $3.2B | $11.1B |
| Share price | $18.75 | $57.23 |
| Change, 1 year | −22.3% | 3.5% |
| Change, 5 years | −2.1% | −37.4% |
| Beta (5Y) | 0.78 | 0.59 |
| Employees | 798 | 3,221 |
| StockData Score | ||
| Total score | 17 (better) | 8 |
| Valuation score | 5 (better) | 1 |
| Growth score | 2 | 3 (better) |
| Performance score | 4 (better) | 2 |
| Health score | 6 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 8.9× (better) | 151× |
| P/S | 2.7× (better) | 3.3× |
| P/B | 2.3× | 1.8× (better) |
| EV/EBITDA | 18.4× (better) | 47.6× |
| P/FCF | 39.4× | 15.0× (better) |
| PEG | – | 4.44 |
| FCF yield | 2.5% | 6.7% (better) |
| Fair value | $31.63 | $30.00 |
| Margin of safety | 40.7% (better) | −90.8% |
| Growth | ||
| Revenue growth (TTM) | 14.8% (better) | 11.2% |
| Revenue growth, 5Y average | 19.4% (better) | 11.6% |
| Net income growth (TTM) | 38.7% (better) | −88.9% |
| EPS growth (TTM) | 35.5% (better) | −88.7% |
| EPS growth, 5Y average | – | −16.7% |
| Profitability | ||
| Gross margin | 90.5% (better) | 76.1% |
| Operating margin | 10.2% (better) | 4.4% |
| Net margin | 30.1% (better) | 2.1% |
| FCF margin | 6.8% | 21.7% (better) |
| Return on equity | 31.4% (better) | 1.2% |
| Return on invested capital | 50.8% (better) | 1.0% |
| Financial health | ||
| Debt / equity | 0.00 | 0.66 (better) |
| Net debt / EBITDA | – | 10.96 |
| Interest coverage | – | 2.0× |
| Current ratio | 3.82 (better) | 2.39 |
| Altman Z-score | 4.94 (better) | 1.84 |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | −1.5% | – |
| Shareholder yield | −1.5% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 97.9% | 101% |
| Held by insiders | 27.8% | 0.52% |
| Insider net buying, 12 months | −$2.5M (better) | −$4.3M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 6.7% | 7.3% |
Go deeper
- ACAD stock overview
- ACAD income statement
- ACAD valuation and score
- BMRN stock overview
- BMRN income statement
- BMRN valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.